Trump’s latest pricing move could be more about polls than patients
President Trump’s 11th-hour move to cap certain drug prices based on what other countries pay is almost certainly going nowhere in the short term. But with 50 days to go before the 2020 election, it could still have political benefits.
As STAT’s Lev Facher and Nicholas Florko report, Trump’s executive order to cap how much Medicare pays for drugs based on lower prices in foreign countries can’t realistically be implemented before Nov. 3, and any attempt to expedite it would get delayed by a legal challenge from the pharmaceutical industry. But campaign experts said the president’s effort, even if it comes to nothing, could prove to be a savvy ploy to appeal to voters who consider drug costs to be a pressing issue.
And it may well pay off. To date, none of Trump’s attempts to rein in drug prices has had a significant effect, but recent polling suggests the so-called most favored nations policy has bipartisan popularity, suggesting the idea, however unlikely to come to fruition, could win over some voters.
Read more.
As STAT’s Lev Facher and Nicholas Florko report, Trump’s executive order to cap how much Medicare pays for drugs based on lower prices in foreign countries can’t realistically be implemented before Nov. 3, and any attempt to expedite it would get delayed by a legal challenge from the pharmaceutical industry. But campaign experts said the president’s effort, even if it comes to nothing, could prove to be a savvy ploy to appeal to voters who consider drug costs to be a pressing issue.
And it may well pay off. To date, none of Trump’s attempts to rein in drug prices has had a significant effect, but recent polling suggests the so-called most favored nations policy has bipartisan popularity, suggesting the idea, however unlikely to come to fruition, could win over some voters.
Read more.
.png)
No hay comentarios:
Publicar un comentario